POLBF - Poolbeg Pharma sees significant commercial opportunity in oral vaccines
(NewsDirect)
PoolbegPharma PLC (AIM:POLB, OTCQB:POLBF) CEO Jeremy Skillington speaks toThomas Warner from Proactive after announcing that work on thecompany's Oral Vaccine Programme collaboration is now set to moveinto a new phase. Taking place over three years, the EncOVacConsortium is funded to develop a Phase I clinical trial ready oralvaccine candidate. Skillington says "as technologies develop, wemove away from injectables so we see great significant commercialopportunities in having an oral alternative." The focus of thenext phase is to commence the validation of the encapsulationprocess.
Contact Details
Proactive UKLtd
+44 20 7989 0813
Copyright (c) 2023 TheNewswire - All rights reserved.